<DOC>
	<DOCNO>NCT02551263</DOCNO>
	<brief_summary>This observational study real-world setting , require determine dosage regimen , dose reduction criterion , rest period criterion withdrawal criterion . The purpose study investigate efficacy eribulin first second line chemotherapy prolong overall survival explore factor affect survival patient HER2-negative hormone-resistant inoperable recurrent metastatic breast cancer schedule receive first second line chemotherapy clinical practice Japan . The total duration study maximum 5 year , consist 2-year enrollment period 3-year observational period ; duration patient participation 3 year . All patient receive adequate treatment breast cancer select primary physician enrollment use Japanese Breast Cancer Society Clinical Practice Guideline Breast Cancer National Comprehensive Cancer Network ( NCCN ) Clinical Practice Guidelines Oncology . Investigators investigational site enter patient data electronic data capture ( EDC ) system third chemotherapy study . The end study define time last patient completes observational period . Patients primarily assess overall survival ( OS ) first line chemotherapy .</brief_summary>
	<brief_title>Eribulin Treatment 1st-line 2nd-line Chemotherapy HER2-negative Hormone-resistant Inoperable Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Female patient histologically cytologically confirm breast cancer . 2 . Patients inoperable recurrent metastatic breast cancer regardless metastatic site number , exclude symptomatic central nervous system metastasis . 3 . Patients HER2negative disease confirm ISH negative IHC 0 , 1+ 2+ ( Those IHC 2+ eligible , additional ISH test result negative . Those ineligible positive result estrogen receptor progesterone receptor test primary recurrent lesion ) . 4 . Patients resistant hormone therapy . 5 . Patients indication first second line chemotherapy HER2negative hormoneresistant inoperable recurrent metastatic breast cancer schedule receive chemotherapy . 6 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status score 03 time enrollment . 7 . Patients adequate bone marrow major organ function judge primary physician . 8 . Patients sign write informed consent participate study . 1 . Patients symptomatic metastasis central nervous system . 2 . Patients previous history hypersensitivity component drug administer treatment . 3 . Patients consider inappropriate study participation primary physician .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Eribulin</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>hormone-resistant</keyword>
	<keyword>inoperable</keyword>
	<keyword>recurrent metastatic</keyword>
</DOC>